Antibodies

Donanemab: breakthrough therapy designation based on TRAILBLAZER data

Lecanemab for the treatment of early Alzheimer’s disease: the story so far

Aducanumab: what’s the latest?

Lecanemab: Phase II open-label extension results

Major ongoing clinical trials in AD: aducanumab, donanemab & lecanemab

Phase III AHEAD 3-45 trial of lecanemab for preclinical Alzheimer’s disease

AAIC 2021 highlights in the vascular space

Approval of aducanumab for Alzheimer’s disease

The future of Alzheimer’s disease: aducanumab

Hopeful developments for Alzheimer’s Disease